Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
HEIDELBERG, Germany, May 17, 2016 -- Affimed (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference – New York, to be held May 23-25, 2016.
Dr. Hoess' presentation will take place May 23, 1:00-1:30 p.m. (ET).
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=78_BOOCR44 or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php.
A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
